Loss of Annexin A10 Expression Is Associated with Poor Prognosis in Early Gastric Cancer.

IF 1.6 4区生物学 Q4 CELL BIOLOGY

Acta Histochemica Et Cytochemica Pub Date : 2020-10-29 Epub Date: 2020-09-24 DOI:10.1267/ahc.20-00014

Akira Ishikawa, Kazuya Kuraoka, Junichi Zaitsu, Akihisa Saito, Toshio Kuwai, Takahisa Suzuki, Hirotaka Tashiro, Kiyomi Taniyama, Wataru Yasui

{"title":"Loss of Annexin A10 Expression Is Associated with Poor Prognosis in Early Gastric Cancer.","authors":"Akira Ishikawa, Kazuya Kuraoka, Junichi Zaitsu, Akihisa Saito, Toshio Kuwai, Takahisa Suzuki, Hirotaka Tashiro, Kiyomi Taniyama, Wataru Yasui","doi":"10.1267/ahc.20-00014","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric cancer (GC) is the third most common cause of cancer-related mortality. The diagnosis and treatment of early GC is a crucial strategy for prognostic improvement of GC. Annexin A10 (ANXA10), a calcium-/phospholipid-binding protein, is a member of the annexin family. The significance of ANXA10 expression in early GC remains unclear. This is the first report to investigate ANXA10 expression in early GC. We performed immunohistochemistry to evaluate ANXA10 expression in early GC, and the correlation between ANXA10 and clinicopathological factors. The loss of ANXA10 expression was detected in 63 (61.2%) of 103 early GC cases and significantly correlated with poor overall survival in patients. Sex, pT stage, pN stage, histology, and ANXA10 expression were associated with poor survival. Sex, histology, and ANXA10 expression were determined as independent predictors of survival in early GC patients. ANXA10 immunostaining could be a new decision-making biomarker in GC.</p>","PeriodicalId":6888,"journal":{"name":"Acta Histochemica Et Cytochemica","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2020-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642482/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Histochemica Et Cytochemica","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1267/ahc.20-00014","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/9/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gastric cancer (GC) is the third most common cause of cancer-related mortality. The diagnosis and treatment of early GC is a crucial strategy for prognostic improvement of GC. Annexin A10 (ANXA10), a calcium-/phospholipid-binding protein, is a member of the annexin family. The significance of ANXA10 expression in early GC remains unclear. This is the first report to investigate ANXA10 expression in early GC. We performed immunohistochemistry to evaluate ANXA10 expression in early GC, and the correlation between ANXA10 and clinicopathological factors. The loss of ANXA10 expression was detected in 63 (61.2%) of 103 early GC cases and significantly correlated with poor overall survival in patients. Sex, pT stage, pN stage, histology, and ANXA10 expression were associated with poor survival. Sex, histology, and ANXA10 expression were determined as independent predictors of survival in early GC patients. ANXA10 immunostaining could be a new decision-making biomarker in GC.

查看原文本刊更多论文

早期胃癌患者Annexin A10表达缺失与预后不良有关

胃癌（GC）是导致癌症相关死亡的第三大常见病因。早期胃癌的诊断和治疗是改善胃癌预后的关键策略。附件蛋白 A10（ANXA10）是一种钙/磷脂结合蛋白，是附件蛋白家族的成员。ANXA10的表达在早期GC中的意义尚不清楚。这是第一份研究 ANXA10 在早期 GC 中表达的报告。我们采用免疫组化方法评估了ANXA10在早期GC中的表达，以及ANXA10与临床病理因素之间的相关性。在103例早期GC病例中，有63例（61.2%）检测到ANXA10表达缺失，且ANXA10表达缺失与患者的总生存率显著相关。性别、pT分期、pN分期、组织学和ANXA10表达与生存率低有关。性别、组织学和ANXA10表达被确定为早期GC患者生存率的独立预测因素。ANXA10免疫染色可能是GC新的决策生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Histochemica Et Cytochemica 生物-细胞生物学

CiteScore

3.50

自引率

8.30%

发文量

审稿时长

>12 weeks

期刊介绍： Acta Histochemica et Cytochemica is the official online journal of the Japan Society of Histochemistry and Cytochemistry. It is intended primarily for rapid publication of concise, original articles in the fields of histochemistry and cytochemistry. Manuscripts oriented towards methodological subjects that contain significant technical advances in these fields are also welcome. Manuscripts in English are accepted from investigators in any country, whether or not they are members of the Japan Society of Histochemistry and Cytochemistry. Manuscripts should be original work that has not been previously published and is not being considered for publication elsewhere, with the exception of abstracts. Manuscripts with essentially the same content as a paper that has been published or accepted, or is under consideration for publication, will not be considered. All submitted papers will be peer-reviewed by at least two referees selected by an appropriate Associate Editor. Acceptance is based on scientific significance, originality, and clarity. When required, a revised manuscript should be submitted within 3 months, otherwise it will be considered to be a new submission. The Editor-in-Chief will make all final decisions regarding acceptance.